Clinical trialNCT03361748CompletedPhase 2Interventional

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

SponsorCelgeneEnrollment149Multiple Myeloma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an open label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture bb2121 chimeric antigen receptor (CAR) modified T cells. Prior to bb2121 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Bristol-Myers Squibb
Bristol-Myers Squibb
Study Director
clinicaltrials.gov ↗
Kristen Hege
Celgene
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

48 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Belgium

Universitaire Ziekenhuizen Leuven
Leuven, Flemish Brabant, Belgium
Local Institution - 201
Leuven, Belgium

Canada

Local Institution - 301
Toronto, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Canada

France

Centre Hospitalier Regional Universitaire de Lille-Hopital Calude Huriez Service Des Maladies Du Sang
Lille, Hauts-de-France, France
Centre Hospitalier Universitaire de Nantes - Hotel Dieu
Nantes, Pays de la Loire Region, France
Local Institution - 402
Lille, France
Local Institution - 401
Nantes, France

Germany

Universitatsklinikum Heidelberg Medizinische Klinik Krehl-Klinik Haematologie, Onkologie, Rheumato
Heidelberg, Baden-Wurttemberg, Germany
University of Tübingen
Tübingen, Baden-Wurttemberg, Germany
Universitatsklinikum Würzburg
Würzburg, Bavaria, Germany
Local Institution - 502
Heidelberg, Germany
Local Institution - 503
Tübingen, Germany
Local Institution - 501
Würzburg, Germany

Italy

Azienda Ospedaliero Universitaria Di Bologna Policlinico
Bologna, Emilia-Romagna, Italy
Local Institution - 602
Bergamo, Italy
Ospedali Riuniti Di Bergamo
Bergamo, Italy
Local Institution - 601
Bologna, Italy

Japan

Tokai University Hospital
Isehara, Kanagawa, Japan
Jichi Medical University Hospital
Shimotsuke, Tochigi, Japan
Japan Red Cross Medical Center
Shibuya-ku, Tokyo, Japan
Local Institution - 803
Isehara City, Kanagawa, Japan
Local Institution - 801
Shibuya-ku, Japan
Local Institution - 802
Shimotsuke, Japan
Local Institution - 804
Shinjuku, Japan
Tokyo Women'S Medical University Hospital
Shinjuku, Japan

Spain

Hospital Universitari Germans Trias I Pujol Can Ruti
Badalona, Barcelona, Spain
Clinica Universidad de Navarra
Pamplona, Navarre, Spain
Local Institution - 702
Badalona (Barcelona), Spain
Local Institution - 701
Pamplona, Spain

United States

Local Institution - 108
San Francisco, California, United States
University of California - San Francisco
San Francisco, California, United States
Emory University
Atlanta, Georgia, United States
Local Institution - 103
Atlanta, Georgia, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Local Institution - 106
Boston, Massachusetts, United States
Local Institution - 107
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Local Institution - 105
Rochester, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States

8 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bb2121 →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 13 Dec 2017
Primary completion: 20 Dec 2023
Completion: 20 Dec 2023
Last update posted: 23 May 2025
Registered enrollment: 149
Registry id: NCT03361748

Cross-registrations

EU-CTR / CTIS (EudraCT)2017-002245-29

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.